Clinical Scorecard: Evolving from BMI to Biological Insights: Bridging the Gap Between Diagnostic Precision and Surgical Candidacy in Obesity Management
Individuals with obesity across BMI ranges, including BMI ≥ 30 kg/m² with metabolic disease and BMI ≥ 35 kg/m² without comorbidities
Care Setting
Metabolic-bariatric surgery eligibility assessment and longitudinal obesity management
Key Highlights
ASMBS/IFSO 2022 guidelines expand surgical eligibility beyond BMI thresholds to include metabolic disease presence and BMI ≥ 35 kg/m² without comorbidities.
2025 Lancet Diabetes & Endocrinology Commission proposes a diagnostic framework differentiating preclinical and clinical obesity based on functional impairment and organ dysfunction.
The diagnostic and therapeutic frameworks are complementary, enabling proportional, risk-stratified obesity care rather than conflicting approaches.
Guideline-Based Recommendations
Diagnosis
Use functional and pathophysiological criteria to define obesity stages (preclinical vs clinical) rather than relying solely on BMI.
Identify clinical obesity by evidence of tissue damage or functional impairment caused by excess adiposity.
Management
ASMBS/IFSO guidelines recommend metabolic-bariatric surgery for patients with BMI ≥ 35 kg/m² regardless of comorbidities and for BMI 30–34.9 kg/m² with metabolic diseases.
In preclinical obesity, prioritize longitudinal monitoring and timely escalation of treatment based on risk progression.
Integrate diagnostic and therapeutic frameworks to align treatment urgency with disease severity.
Monitoring & Follow-up
Implement active surveillance in preclinical obesity similar to other chronic diseases, monitoring for emerging or worsening risk indicators.
Use risk stratification tools that consider disease trajectory, context, and potential for functional decline.
Risks
Limited high-quality evidence exists for surgery in patients with BMI ≥ 35 kg/m² without comorbidities; current recommendations rely on expert consensus and observational data.
Risk of overtreatment if surgical intervention is applied without considering functional impairment or disease severity.
Patient & Prescribing Data
Patients with obesity across a range of BMI values, including those with metabolic comorbidities and those without but at risk.
Expanding surgical eligibility criteria aims to improve access and metabolic risk mitigation; however, treatment should be proportionate to disease severity and functional impairment.
Clinical Best Practices
Adopt a dual-framework approach combining ASMBS/IFSO surgical eligibility criteria with the Lancet Commission’s diagnostic staging for comprehensive obesity care.
Prioritize early intervention in patients with metabolic disease even at lower BMI thresholds to prevent irreversible complications.
Use longitudinal follow-up and risk monitoring in preclinical obesity to guide timely escalation of therapy.
Ensure equitable access to metabolic-bariatric surgery while aligning treatment decisions with biological disease markers and functional status.
